Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)

Blood

Volumn 94, Issue 7, 1999, Pages 2217-2224

  Winkler, U ^a   Jensen, M ^a   Manzke, O ^a   Schulz, H ^a   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTOKINE; D DIMER; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIVER ENZYME; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER REGRESSION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DYSPNEA; FEMALE; FEVER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; VOMITING;

EID: 0033214207     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2217.419k02_2217_2224     Document Type: Article

References (23)

1. Byrd JC, Rai KR, Sausville EA, Grever MR: Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals. Semin Oncol 25:65, 1998
2. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles T-M, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266, 1997
3. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczmann MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825, 1998
4. Nguyen DT, Amess JA, Doughthy H, Hendry L, Diamond LW: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62:76, 1999
5. Jensen M, Winkler U, Manzke O, Diehl V, Engert A: Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Haematol 77:89, 1998
6. O'Brien S, Freireich E, Andreeff M, Lerner S, Keating M: Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL). Blood 92:105a, 1998 (abstr)
7. Österborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H, European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567, 1997
8. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antmann KH, Schlossmann SF: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res 40:3147, 1980
9. Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085, 1984
10. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 93:151, 1996
11. Shan P, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644, 1998
12. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188, 1997
13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990, 1996
14. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA: Rituximab therapy in hematologic malignancy: Patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791, 1999
15. Michie HR, Manogue KR, Spriggs DR, RevhaugA, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
16. Griffin GE: Cytokines involved in human septic shock - the model of the Jarisch-Herxheimer reaction. J Antimicrob Chemother 41:25, 1998 (suppl A)
17. Negussie Y, Remick DG, De Forge LE, Kunkel SL, Eynon A, Griffin GE: Detection of plasma tumour necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J Exp Med 175:1207, 1992
18. Gaston RS, Zeierhoi MH, Patterson T, Parsthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ: OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 39:141, 1991
19. Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A: Mechanism of first-dose cytokine-release syndrome by Campath 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819, 1996
20. Tibben JG, Boerman OC, Claessens RA, Corstens FH, van Deuren M, de Mulder PH, van der Meer JW, Keijser KG, Massuger LF: Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2 (letter). J Natl Cancer Inst 85:1003, 1993
21. van Buchem MA, Levelt CA, Hogendoorn P, Colly LP, Kluin PM, Willemze R, Daha MR: Involvement of the complement system in the pathogenesis of pulmonary leukostasis in experimental myelocytic leukemia. Leukemia 7:1608, 1993
22. Tefferi A, Bartholmai BJ, Witzig TE, Li C-Y, Hanson CA, Phyliky RL: Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Clin Pathol 106:457, 1996
23. Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y: Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 89:748, 1998